Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

Erasca, Inc. (NASDAQ: ERAS) stock plummeted 48% ($9.25) after the company disclosed a patient death following ERAS-0015 treatment and faced patent infringement accusations from Revolution Medicines. The company allegedly misled investors about the drug's efficacy comparisons and intellectual property protection. The disclosures wiped out $2.8 billion in market capitalization, prompting a securities class action lawsuit covering the period from January 14, 2025 to April 26, 2026.